Virus Outbreak Pfizer

In this March 2, 2021, file photo, pharmacy technician Hollie Maloney loads a syringe with Pfizer’s COVID-19 vaccine at the Portland Expo in Portland, Maine. The U.S. gave full approval to Pfizer’s COVID-19 vaccine on Monday, Aug. 23, 2021.

Support Local Journalism

WASHINGTON (AP) — The U.S. gave full approval to Pfizer’s COVID-19 vaccine Monday, a milestone that could lift public confidence in the shots and spur more companies, universities and local governments to make vaccinations mandatory.

The formula made by Pfizer and its German partner BioNTech now carries the strongest endorsement from the Food and Drug Administration, which has never before had so much evidence to judge a shot’s safety.

More than 200 million Pfizer doses have been administered in the U.S. — and hundreds of millions more worldwide — since December. But up to now, they were dispensed in this country under what is known as emergency use authorization from the FDA.

“The public can be very confident that this vaccine meets the high standards for safety, effectiveness and manufacturing quality the FDA requires of an approved product,” acting FDA Commissioner Janet Woodcock said in announcing full approval, which comes as the U.S. battles the most contagious coronavirus mutant yet, the delta variant.

Pfizer CEO Albert Bourla said in a statement he hopes the decision “will help increase confidence in our vaccine, as vaccination remains the best tool we have to help protect lives.” The shot now will be known in the U.S. by the brand name Comirnaty.

U.S. vaccinations bottomed out in July at an average of about a half-million shots per day, down from a peak of 3.4 million a day in mid-April. As the delta variant fills hospital beds, shots are on the rise again, with a million a day given Thursday, Friday and Saturday.

Just over half of the U.S. population is fully vaccinated with one of the country’s three options, from Pfizer, Moderna or Johnson & Johnson.

Moderna has also applied to the FDA for full approval of its vaccine. J&J said it hopes to do so later this year.

Full approval means Pfizer’s COVID-19 vaccine meets the same “very high standards required of all the approved vaccines we rely on every day,” said Dr. Jesse Goodman of Georgetown University, a former FDA vaccine chief. That should help “anyone who still has concerns gain confidence” in the shots.

The FDA’s action may also lead to more vaccine mandates covering students, employees and customers.

“Mandating becomes much easier when you have full approval,” said Dr. Carlos del Rio of Emory University. “I think a lot of businesses have been waiting for it.”

Please be aware that Cache Valley Publishing does not endorse, and is not responsible for alleged employment offers in the comments.

Recommended for you